WIN378 Asthma Trial: The Twice-Yearly TSLP Challenge
Witfire Elite | Clinical Catalysts | Respiratory Medicine The latest WIN378 asthma data suggest that the biological effects of a single dose can last…
Witfire Coverage
Category: Pharma News
BV100 Philippines Trial: Two Hospitals, Revised Timelines
Witfire Elite | Philippines Pharma Watch | BV100 Philippines trial The BV100 Philippines trial plan names two hospitals and a target of 20 participants.…
Nerandomilast Philippines: Three Hospitals Listed
Witfire Elite | Philippines Pharma Watch | Clinical Catalysts | Nerandomilast Philippines Nerandomilast Philippines trial plans now list three hospitals and a target of…
RENGEVITY-201 Trial: Pegrizeprument Takes On Tacrolimus
Witfire Elite | Clinical Catalysts | Trial Design Audit RENGEVITY-201 trial dosing has begun, Veloxis says, with the first participant now treated. The Phase…
Alevia-B: Pascual Lab’s Pain and Mobility Push
Witfire Elite | Philippines Pharma Watch | OTC Formulation Audit Alevia-B is receiving fresh coverage in the Philippines through PascualLab’s 80th-anniversary portfolio campaign. Each…
Philippine FDA CPR Renewal Rule: Advisory 2026-1007
Witfire Elite · FDA & Regulatory Intelligence · Philippines Pharma Watch The FDA CPR renewal rule is narrower than a general grace period. A…
PULSE-LHD Trial Enrols First U.S. Patients
Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates…
Ravulizumab ARTEMIS: 555 Patients, Six Terminations, and a Mechanism That Did Not Travel
Witfire Elite · Clinical Catalysts · Registry Analysis The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed…
OX40 Atopic Dermatitis: A Drug Class Ended in 175 Days and 8,185 Patients
Witfire Elite · Clinical Catalysts · Registry Analysis OX40 atopic dermatitis development is over. Two companies, two mechanisms, 175 days. The press releases said…
Teva Q2 2026 Results: What the Numbers Actually Say
Teva's Q2 2026 revenue fell 1%, operating income fell $686M and the shares rose 8.6%. All three follow from one subtraction the release never performs: US generics lost $301M in the quarter, and three branded products added $306M.